Phase II trial of fulvestrant (Faslodex) in women with metastatic breast cancer and failure on aromatase inhibitor therapy

Trial Profile

Phase II trial of fulvestrant (Faslodex) in women with metastatic breast cancer and failure on aromatase inhibitor therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2015

At a glance

  • Drugs Fulvestrant (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 16 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top